Upper/Lower Gastrointestinal Symptoms Adverse event reporting databases, RCTs, and real-world data consistently show that GLP-1 RAs are commonly associated with GI symptoms such as nausea, vomiting, diarrhea, constipation, abdominal pain, and dyspeptic complaints
Combination focus: Much of its regulatory development is tied to dual-therapy use with GLP-1 drugs, positioning it as a combination obesity therapy rather than a standalone peptide
Before procedures/anesthesia: Current multi-society guidance says most patients can continue GLP-1s, but plans should be individualized with your surgeon/anesthesiologistespecially if you have significant GI symptoms
for forearm fracture the crude HR was 1.12 [0.851.47] and the fully adjusted HR 1.06 [0.791.41], and for any fracture the crude HR was 1.01 [0.901.13], and the fully adjusted HR was 0.97 [0.86-1.09] when comparing GLP-1 RAs with DPP-4is
The other twelve names appear briefly in a list, but MEDVi gets paragraphs: The plaintiff purchased oral tirzepatide through MEDVi specifically MEDVi is the only storefront whose corporate history the complaint traces (incorporated in Delaware, April 2024) Its the only one whose litigation history is cited (the Siuksta non-appearance)
Continue for 16 to 24 weeks minimum before assessing results